FilingsTodayBeOne Medicines
At a glance
BeOne Medicines reported 2025 revenue of $5.34B, up 40.2% from $3.81B in 2024. Over 4 years since 2021 ($1.18B), that is growth of about 46% a year. Operating margin was 8.4%, up from -122.3% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2021, 2022, 2023 and 2024.
In the last 12 months 10 insiders reported 0 open-market purchases and 50 sales ($391.2M). 23 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $89.4M by Chief Executive Officer John Oyler on Jul 17, 2026.
BeOne Medicines filed 12 current reports (Form 8-K) in the last 12 months, most often for results of operations (6), other events (2), officer or director change (2) and shareholder vote results (1). The latest officer or director change was reported on Jun 11, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.
1 of the 20 investors tracked here held BeOne Medicines at the last quarter end, worth $29.1M combined. It is the largest weight for Renaissance Technologies (0% of its portfolio). Added: Renaissance Technologies.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$1.46B | -$2B | -$881.7M | -$644.8M | $286.9M |
| Diluted EPS | $-1.21 | $-1.49 | $-0.65 | $-0.47 | $0.19 |
Fiscal year ends Dec 31
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined